#United States #New York #Kessler Topaz #Securities Fraud #Applied Therapeutics

Kessler Topaz Meltzer & Check, LLP Files Class Action Against Applied Therapeutics

A significant development has emerged for investors in the biotechnology sector as Kessler Topaz Meltzer & Check, LLP announced the initiation of a class action lawsuit against Applied Therapeutics, Inc. This legal action is a response to alleged securities fraud that impacted investors who purchased Applied Therapeutics shares between January 3, 2024, and December 2, 2024. The lawsuit has been filed in the United States District Court for the Southern District of New York, marking a critical juncture for affected parties seeking restitution.

Allegations Against Applied Therapeutics

The lawsuit alleges that throughout the specified Class Period, executives at Applied Therapeutics made a series of misleading statements and failed to disclose vital information regarding the company’s clinical trials. Specifically, the complaint claims that there were serious deviations from the required trial protocols for their drug candidate, govorestat. This non-compliance raised red flags, suggesting that the data collected might not be accepted by the FDA during the submission for a New Drug Application (NDA). Such risks not only jeopardize the integrity of the drug development process but also significantly affect investor confidence and market valuation.

Importance of the Lead Plaintiff Process

For investors who experienced financial losses due to these developments, there is a crucial deadline approaching. Those who wish to be appointed as the lead plaintiff in this class action have until February 18, 2025, to make their intentions known. The role of the lead plaintiff is essential; it represents the interests of all class members in directing the litigation and making critical decisions during the process.

If investors choose to participate in the lawsuit, they will join many others affected by the actions of Applied Therapeutics. Investors have the option to seek representation through Kessler Topaz Meltzer & Check or may opt to remain silent members of the class, foregoing any active role in the proceedings.

How to Get Involved

To express interest in becoming a lead plaintiff or to acquire more information on the proceedings, investors can directly contact Kessler Topaz Meltzer & Check, LLP. Their legal team is prepared to assist those affected by the alleged misconduct, providing necessary guidance and support throughout the litigation process.

The firm has made it easy for individuals to get involved, offering links and contact details for inquiries. Potential class members may contact attorney Jonathan Naji at (484) 270-1453 or via email at [email protected] Additionally, a link for sign-up, and detailed information about the case, is available on Kessler Topaz's official website.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP has built a reputation as a leading firm in prosecuting class actions across various sectors, focusing predominantly on securities fraud. Their commitment to protecting investors has seen them recover billions in damages due to corporate misconduct. The firm's extensive experience showcases their ability to navigate complex legal landscapes effectively.

As investors brace for potentially significant outcomes from this lawsuit, staying informed and ready to act is crucial. This class action serves as a reminder of the vigilance needed in investing, especially within volatile sectors like biotech.

For more detailed updates on this case, investors can stay tuned through the Kessler Topaz’s communications.